← Back to Clinical Trials
Recruiting NCT06126419

Application of High-dose Insulin Therapy to Improve Liver Function and Regeneration

Trial Parameters

Condition Liver Dysfunction
Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Study Type INTERVENTIONAL
Phase N/A
Enrollment 70
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-11-08
Completion 2026-07
Interventions
High-Dose Insulin Therapy

Brief Summary

The primary objective of this interventional study is determine if the future liver remnant can be optimized by improving liver function pre-operatively in patients who are scheduled for major hepatectomy. The main questions it aims to answer are: 1. Does high-dose insulin therapy improve liver function in the pre-operative setting? 2. What is the effect of high-dose insulin therapy on liver function and liver regeneration after a liver venous deprivation (LVD) procedure? 3. What is the relationship between volume hypertrophy and function in the regenerating liver? Participants will receive a 6-hour infusion of insulin and dextrose to maintain a hyperinsulinemic-normoglycemic state in the weeks prior to planned liver surgery to assess its effect on liver function measured by 99m-Tc-Mebrofenin hepatobiliary scintigraphy.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years old * Candidate for major liver resection * Resectable colorectal liver metastasis Exclusion Criteria: * Inability to give consent * Type 1 diabetes mellitus * Uncontrolled blood glucose levels (fasting level \> 10 mmol/L) * Unresectable colorectal liver metastasis * Extrahepatic metastatic disease that is unresectable

Related Trials